Umang Vohra was previously Dr Reddy’s Laboratories’s Chief Financial Officer in India
Dr Reddy’s Laboratories North America head Umang Vohra has quit the company. Vohra was previously the company’s chief financial officer (CFO) in India. Besides, he also handled functions like mergers and acquisitions, operational efficiency and de-risking strategies during his 13-year tenure at Dr Reddy’s.
Revenues from North America contributes 60 per cent to the company’s generics business and hence Vohra was a key man.
In a statement the company said, “Umang Vohra is moving out of the organisation and has stepped down from the position of Executive Vice-President and Head North America Generics. Alok Sonig, Executive Vice-President and Head India Generics will now take over as executive vice-president & Head North America Generics.”
Vohra served as the Chief Financial Officer of Dr Reddy’s Laboratories from January 2009 to December 2012. He was Senior Vice-President and Vice-President and his elevation was part of its leadership development and transition programme. He joined Reddy’s in 2002 from PepsiCo and has been part of several key initiatives like acquisitions, R&D de-risking transactions and operational improvements in accounting, governance and finance processes.
Vohra is being replaced by Alok Sonig, who is currently responsible for the Indian market and is a member of the management council at the company. Before moving to Dr Reddy’s in 2012, Sonig had worked for Bristol-Myers Squibb as its India chief from 2007. He was also placed in the US by BMS to drive its commercial excellence and business model innovation functions at Princeton, New Jersey.
“MV Ramana, who is currently Executive Vice-President – Emerging Markets, has assumed additional charge and is now Executive Vice-President and Head branded markets (India and emerging countries),” the company said.